FDA expands Casgevy approval to children 2 years and older with sickle cell disease

The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and transfusion-dependent beta thalassemia. Previously approved for patients aged 12 years and older, Casgevy (exagamglogene autotemcel, Vertex Pharmaceuticals/CRISPR Therapeutics) is now the first and only gene therapy available for use in patients as young as 2 years with